Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

500 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21).
Iriyama N, Hatta Y, Takeuchi J, Ogawa Y, Ohtake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, Izumi T, Sakamaki H, Miyawaki S, Honda S, Miyazaki Y, Taki T, Taniwaki M, Naoe T. Iriyama N, et al. Among authors: sakamaki h. Leuk Res. 2013 Sep;37(9):1021-6. doi: 10.1016/j.leukres.2013.05.002. Epub 2013 Jun 28. Leuk Res. 2013. PMID: 23810283 Clinical Trial.
Randomized trials between behenoyl cytarabine and cytarabine in combination induction and consolidation therapy, and with or without ubenimex after maintenance/intensification therapy in adult acute myeloid leukemia. The Japan Leukemia Study Group.
Kobayashi T, Miyawaki S, Tanimoto M, Kuriyama K, Murakami H, Yoshida M, Minami S, Minato K, Tsubaki K, Ohmoto E, Oh H, Jinnai I, Sakamaki H, Hiraoka A, Kanamaru A, Takahashi I, Saito K, Naoe T, Yamada O, Asou N, Kageyama S, Emi N, Matsuoka A, Tomonaga M, Ohno R, et al. Kobayashi T, et al. Among authors: sakamaki h. J Clin Oncol. 1996 Jan;14(1):204-13. doi: 10.1200/JCO.1996.14.1.204. J Clin Oncol. 1996. PMID: 8558199 Clinical Trial.
Significant reduction of medical costs by differentiation therapy with all-trans retinoic acid during remission induction of newly diagnosed patients with acute promyelocytic leukemia. The Japan Adult Leukemia Study Group.
Takeshita A, Sakamaki H, Miyawaki S, Kobayashi T, Kuriyama K, Yamada O, Oh H, Takenaka T, Asou N, Ohno R. Takeshita A, et al. Among authors: sakamaki h. Cancer. 1995 Aug 15;76(4):602-8. doi: 10.1002/1097-0142(19950815)76:4<602::aid-cncr2820760410>3.0.co;2-l. Cancer. 1995. PMID: 8625153
Morphological subtyping of acute myeloid leukemia with maturation (AML-M2): homogeneous pink-colored cytoplasm of mature neutrophils is most characteristic of AML-M2 with t(8;21).
Nakamura H, Kuriyama K, Sadamori N, Mine M, Itoyama T, Sasagawa I, Matsumoto K, Tsuji Y, Asou N, Kageyama SI, Sakamaki H, Emi N, Ohno R, Tomonaga M. Nakamura H, et al. Among authors: sakamaki h. Leukemia. 1997 May;11(5):651-5. doi: 10.1038/sj.leu.2400618. Leukemia. 1997. PMID: 9180287
Response-oriented individualized induction therapy followed by intensive consolidation and maintenance for adult patients with acute lymphoblastic leukemia: the ALL-87 study of the Japan Adult Leukemia Study Group (JALSG).
Tanimoto M, Miyawaki S, Ino T, Kyo T, Sakamaki H, Naoe T, Hiraoka A, Asou N, Ohshima T, Tsubaki K, Kuriyama K, Ueda T, Minamil S, Okabe K, Saito H, Murakami H, Hirano M, Dohy H, Onozawa Y, Suzuki H, Ohno R. Tanimoto M, et al. Among authors: sakamaki h. Int J Hematol. 1998 Dec;68(4):421-9. doi: 10.1016/s0925-5710(98)00084-x. Int J Hematol. 1998. PMID: 9885441 Clinical Trial.
No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group.
Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Omoto E, Kuriyama K, Hatake K, Saito K, Kanamaru A, Oh H, Ohtake S, Asou N, Sakamaki H, Yamada O, Jinnai I, Tsubaki K, Takeyama K, Hiraoka A, Matsuda S, Takahashi M, Shimazaki C, Adachi K, Kageyama S, Ohno R, et al. Miyawaki S, et al. Among authors: sakamaki h. Int J Hematol. 1999 Aug;70(2):97-104. Int J Hematol. 1999. PMID: 10497848 Clinical Trial.
Cytogenetic heterogeneity of acute myeloid leukaemia (AML) with trilineage dysplasia: Japan Adult Leukaemia Study Group-AML 92 study.
Miyazaki Y, Kuriyama K, Miyawaki S, Ohtake S, Sakamaki H, Matsuo T, Emi N, Kobayashi T, Matsushima T, Shinagawa K, Ohno R, Tomonaga M; Japan Adult Leukaemia Study Group. Miyazaki Y, et al. Among authors: sakamaki h. Br J Haematol. 2003 Jan;120(1):56-62. doi: 10.1046/j.1365-2141.2003.03981.x. Br J Haematol. 2003. PMID: 12492577 Free article.
[Progress in therapy for leukemia and the diagnosis (discussion)].
Nitta M, Miyawaki S, Sakamaki H, Onishi K, Kusumoto S. Nitta M, et al. Among authors: sakamaki h. Nihon Naika Gakkai Zasshi. 2003 Jun 10;92(6):1048-64. Nihon Naika Gakkai Zasshi. 2003. PMID: 12866453 Japanese. No abstract available.
Nonmyeloablative stem cell transplantation with fludarabine and cyclophosphamide for patients with hematologic malignancies.
Nakajima H, Oki M, Kishi K, Ueyama J, Miyakoshi S, Hatsumi N, Sakura T, Miyawaki S, Yokota A, Fujisawa S, Mori S, Tanaka Y, Sakamaki H; Kanto Study Group for Cell Therapy. Nakajima H, et al. Among authors: sakamaki h. Clin Lab Haematol. 2003 Dec;25(6):383-91. doi: 10.1046/j.0141-9854.2003.00550.x. Clin Lab Haematol. 2003. PMID: 14641143 Clinical Trial.
500 results